Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has said its Head of Clinical Operations, Fayaz Master will deliver a poster presentation at the American Association for Cancer Research (AACR) annual meeting which "introduces the concept of citrullination as a good target for cancer vaccines".
The poster, titled 'Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian carcinoma: protocol for the ModiFY phase I/II basket clinical trial', will be presented at the Orange County Convention -Center in Orlando, Florida, at the session from 1.30pm-5.30pm ET today, Tuesday, 18 April, 2023.
The developer of novel immunotherapies for the treatment of cancer and infectious disease said the poster, which includes data up until the date of the poster acceptance by AACR, "concludes that Modi-1 is well tolerated and that the early efficacy data from the monotherapy arm of the trial is encouraging".
The ModiFY study is currently recruiting patients into the Phase 2a sub-study investigating Modi-1 monotherapy, with patients also being screened for treatment with Modi-1 in combination with standard-of-care CPI therapy.